Please assess the completion status of the following clinical trial:

Trial Title: Airway Pressure Release Ventilation in Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Acute onset of:~1. Arterial Pressure of Oxygen (PaO2) / FiO2 ≤ 300~2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph. The infiltrates may be patchy, diffuse, homogeneous, or asymmetric~3. Requirement for positive pressure ventilation via endotracheal tube, and~4. No clinical evidence of left atrial hypertension.~5. Receiving conventional MV, or lung-protective ventilation (LPV), in the assist control (AC) mode with positive end-expiratory pressure (PEEP) \> 5 cm H2O Criteria 1-3 must occur within a 24-hour period. Acute onset is defined as follows: the duration of the hypoxemia criterion (#1) and the chest radiograph criterion (#2) must be \< 7 days at the time of randomization.~Exclusion Criteria:~1. FiO2 \> 70% or PaO2/FiO2 \< 125 or arterial pH \< 7.25~2. Greater than 6 days since all inclusion criteria are met~3. Anticipated to begin weaning from MV within 48 hours~4. Neuromuscular disease that prevents the ability to generate spontaneous tidal volumes.~5. Glasgow Coma Scale (GCS) \< 15 within 1 week of intubation~6. Acute stroke (vascular occlusion or hemorrhage)~7. Current alcoholism or previous daily use of opioids or benzodiazepines before hospitalization~8. Acute meningitis or encephalitis~9. Pregnancy (negative pregnancy test required for women of child-bearing potential) or breast-feeding.~10. Severe chronic respiratory disease~11. Previous barotraumas during the current hospitalization~12. Clinical evidence of bronchoconstriction on bedside examination (i.e., wheezing).~13. Patient, surrogate, or physician not committed to full support~14. Severe chronic liver disease (Child-Pugh Score B or C)~15. International Normalized Ratio (INR) \> 2.0~16. Platelet level \< 50,000~17. Mean arterial pressure \< 65, or patient receiving intravenous vasopressors (any dose of epinephrine, norepinephrine, phenylephrine, or dopamine \> 5 mcg/kg/min)~18. Age \< 16 years old~19. Morbid obesity (greater than 1kg/cm body weight).~20. No consent/inability to obtain consent~21. Unwillingness of the clinical team to use conventional low tidal-volume protocol for MV.~22. Moribund patient not expected to survive 24 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APRV (Type: EXPERIMENTAL): Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
- Conventional MV (Type: ACTIVE_COMPARATOR): Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.

Based on this trial design, predict the completion outcome and termination type (if applicable).